Understanding clinical trials and device coverage
Clinical trials background
What regulatory guidance addresses devices and clinical trials in the Medicare program?
For guidance...
Articles
Article Type
Category
Contractor Advisory Committee (CAC) meeting fact sheet
The CAC is used to supplement the MAC’s internal expertise and to ensure an unbiased and contemporary consideration of “state of...
NCD 110.24: Chimeric Antigen Receptor (CAR) T-cell therapy
Effective for dates of service on or after August 7, 2019, Medicare will pay claims from approved providers for administration...
Avoid negative impacts to your claims -- review billing and coding article A58918 molecular pathology and genetic testing
View this important information you must know if you bill for molecular pathology and genetic testing. This article was updated...
Prior authorization for ambulance transports is for repetitive transports
A repetitive service is defined as medically necessary ambulance transportation that is furnished three or more times during a...
Provide your correct PTAN when contacting provider customer service
Make sure to provide your correct PTAN in the proper format when contacting us for any claim-related inquiries. PTANs that have...
‘Reasonable and necessary’ guidelines
View these guidelines regarding what it means for a service to be "reasonable and necessary."
Open meeting fact sheet
The purpose of the open meeting is to allow interested parties the opportunity to make presentations of information and offer...
Freedom of Information Act requests
FOIA (Freedom of Information Act) found in Title 5 of the United States Code, section 552, and enacted in 1966, provides that...
SPRAVATO® (esketamine) nasal spray CIII place of service (POS) requirements
View our latest article on SPRAVATO® (esketamine) nasal spray - used to treat treatment-resistant depression in adults - and its...